SEC Form 4 · accession 0000899243-18-031647
Clovis Oncology, Inc. · CLVS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lindsey Rolfe
Officer — See Remarks
Period of report
Dec 20, 2018
Accepted (ET)
Dec 26, 2018 · 9:00 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001466301
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 20, 2018 | M | 3,438 | — | A | 17,600 | D | |
| Common StockF2 | Dec 20, 2018 | S | 1,728 | $17.72 | D | 15,872 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF3,F1 | — | Dec 20, 2018 | M | 3,438 | D | — | — | Common Stock | 3,438 | 27,500 | D |
Explanation of responses
- F1Each Restricted Stock Unit represents the right to receive one share of Common Stock.
- F2Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person.
- F3On December 19, 2016, the reporting person was granted 55,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on December 19, 2017, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
Remarks
Chief Medical Officer and Executive Vice President of Clinical and Preclinical Development and Pharmacovigilance